BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 20/11/2015

FDA Clears LIPTRUZET Tablets for Approval

The FDA has determined that LIPTRUZET tablets, containing ezetimibe and atorvastatin, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of generic versions of the medication.

Source: Federal Register — Food and Drug AdministrationOpen original release →